Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF Mutant Metastatic Colorectal Cancer Patients

PURPOSE: BRAF mutant metastatic colorectal cancer (mCRC) forms an aggressive subset of colorectal cancer with minimal response to selective RAF inhibitors. Preclinical data show that reactivation of epidermal growth factor receptor (EGFR) signaling occurs in colorectal tumor cells treated with RAF i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Yaeger, Rona, Cercek, Andrea, O'Reilly, Eileen M., Reidy, Diane L., Kemeny, Nancy, Wolinsky, Tamar, Capanu, Marinela, Gollub, Marc J., Rosen, Neal, Berger, Michael F., Lacouture, Mario E., Vakiani, Efsevia, Saltz, Leonard
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546416/
https://ncbi.nlm.nih.gov/pubmed/25589621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-2779
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados